Stocks Listing
GLPG.AS

Galapagos NV

Share
GLPG.AS
$47.59 0.08%Last Updated Nov 25 2022 05:45 PM
1D Low / 1D High
Low:$47.27
High:$47.61
1D
0.08%
5D
1.06 %
30D
13.35 %
BulletPurple
Market Cap
$3,167,459,526
0.08 %
3.2 B
BulletBlue
Volume 1D
100,594
-
100.6 K
BulletOrange
Circulating Supply
66,562,700 GLPG.AS
66.6 M

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Opened
AMS
Euronext Amsterdam Stock Exchange
NLD
Closes in
1 hour, 52 minutes
Working Hours
Mon-Fri, 08:00 AM - 06:30 PM
Timezone
GMT+0